NXI Therapeutics AG

NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, Switzerland and is committed to creating tomorrow’s safe immunotherapies by leveraging a novel targeted approach in T cell immunology. NXI Therapeutics is pioneering the development of selective immunomodulators that target the Coronin 1 pathway, which regulates those T cell immune responses that play a key
role in graft rejection and autoimmunity, while leaving the protective responses against infections and vaccination intact.